Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.42 |
| ▸ | INSR | P06213 | 12/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293192 | 0.93 | MET (0.43) | METINSRJAK1TYK2JAK2 | |
| SCHEMBL1293031 | 0.92 | MET (0.42) | METINSRJAK1TYK2MAPK3 | |
| SCHEMBL12103383 | 0.92 | MAPK3 (0.42) | METINSRJAK1TYK2JAK2 | |
| SCHEMBL1293028 | 0.89 | MET (0.41) | METINSRJAK1TYK2MAPK3 | |
| SCHEMBL1293073 | 0.89 | PTK2 (0.47) | METINSRJAK1TYK2JAK2 | |
| SCHEMBL1293095 | 0.85 | MAPK1 (0.43) | METINSRJAK1TYK2MAPK3 | |
| SCHEMBL12103254 | 0.84 | JAK1 (0.43) | METINSRJAK1TYK2JAK2 | |
| SCHEMBL690567 | 0.84 | PTK2 (0.50) | METINSRJAK1TYK2PTK2 | |
| SCHEMBL690644 | 0.83 | MAPK3 (0.42) | METINSRJAK1TYK2MAPK3 | |
| SCHEMBL12349650 | 0.83 | JAK1 (0.43) | METINSRJAK1TYK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269774-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | MET 1274/4885INSR 1704/4885JAK1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.